CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Cryoablation of Prostate Cancer Policy

Policy governs coverage of percutaneous cryoablation (cryotherapy/cryosurgery) of the prostate for treatment of clinically localized (organ-confined) prostate cancer as initial therapy or as salvage therapy after radiation therapy for Commercial Products. Excludes BlueCHiP for Medicare which is covered by a related policy.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyCryoablation of Prostate Cancer Policy

Policy CodePolicy N/A

Change TypeNo material change

Effective Date

Next Review Date

Key ActionDocument diagnosis of clinically localized (organ-confined) prostate cancer and indicate whether cryoablation is initial therapy or salvage therapy after radiation; verify member-specific benefits and eligibility.

SourceLink

POLICY UPDATE CHANGES

No material changes to clinical evidence or coverage criteria.

1Covered CPT code

CommercialApplicable product line

Coverage Summary

Scope: This policy governs percutaneous cryoablation (cryotherapy/cryosurgery) of the prostate for treatment of clinically localized (organ-confined) prostate cancer when performed as initial therapy or as salvage therapy after radiation for Commercial products. Note: this policy applies to Commercial Products only and excludes BlueCHiP for Medicare, which is covered by a related policy.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical‑Necessity Criteria

Medically Necessary Indications

Cryoablation of the prostate is considered medically necessary when the following are met:

ALL of the following

Diagnosis of clinically localized (organ-confined) prostate cancer
Treatment setting
- Performed as initial treatment
- Performed as salvage treatment for disease that recurs following radiation therapy

ref": "b1_0

title": "Medically Necessary Indications

Clinically localized (organ-confined) prostate cancer: Prostate cancer that is confined to the prostate gland as documented by standard diagnostic evaluation and biopsy.

Whole-gland (total) cryoablation: Cryoablation applied to the entire prostate gland as definitive therapy, typically performed by percutaneous insertion of cryoprobes to freeze and thaw prostate tissue.

Subtotal (focal) cryoablation: Cryoablation targeted to part of the prostate (an emerging/alternative technique rather than whole-gland treatment).

Provider Actions

Documentation Required

Document diagnosis and treatment intent

Provider must document diagnosis of clinically localized (organ-confined) prostate cancer and indicate whether cryoablation is being performed as initial therapy or as salvage therapy after radiation.

55873

Billing Rule

Verify benefits and eligibility

Benefits and coverage may vary by group and contract; providers must verify member-specific benefits and eligibility with the Evidence of Coverage or Subscriber Agreement and the provider call center.

Check member-specific benefits and provider call center

Background & Evidence

Technique: Cryoablation (cryotherapy/cryosurgery) involves percutaneous insertion of thin, needle-like cryoprobes into the prostate and delivery of very cold gas to rapidly freeze and thaw tissue, causing necrosis.

Evidence summary: For whole-gland cryoablation as initial therapy, evidence includes systematic reviews, randomized controlled trials, and comparative and noncomparative observational studies showing similar overall and disease-specific survival compared with radical prostatectomy and external-beam radiotherapy; the evidence is considered sufficient to determine a meaningful improvement in net health outcome. For salvage whole-gland cryoablation after radiotherapy, the evidence is primarily noncomparative case series and retrospective studies, but is considered sufficient to determine meaningful improvement in net health outcome for men with recurrent disease.

Evidence strength

Evidence strength for whole-gland cryoablation (initial therapy)Sufficient to determine meaningful improvement in net health outcome

Evidence strength for salvage whole-gland cryoablationSufficient to determine meaningful improvement in net health outcome (primarily noncomparative series and retrospective studies)

Name	Type	Number	Effective Date
Focal Treatments for Prostate Cancer (related policy)	NCD